adamas pharmaceuticals  homepage adamas contact home timing mattersdeveloping therapies for people with chronic neurologic disorders overviewadamas develops new medicines to improve the lives of people affected by chronic neurologic disorders about adamas ads in levodopainduced dyskinesiawe are developing an amantadine therapy for the treatment of levodopainduced dyskinesia in people with parkinsons disease learn more product pipeline overview adamas develops new medicines to improve the lives of people affected by chronic neurologic disorders about adamas recent news adamas reports inducement grant to new chief financial officer jul   adamas appoints new chief financial officer jun   adamas announces publication of ads phase  ease lid clinical trial in jama neurology jun   adamas presents expanded analysis from the ads openlabel study showing tolerability and durability out to  weeks jun   adamas to present at two upcoming investor conferences jun   adamas pharmaceuticals  about adamas adamas contact home about adamas adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders approximately  million people in the united states suffer from conditions such as parkinson’s disease multiple sclerosis epilepsy and alzheimer’s disease symptoms associated with these disorders can be treated suboptimally due to tolerability issues which may limit the amount of drug that is present when patients need relief adamas has pioneered a platform to develop medicines for chronic neurologic disorders based upon an understanding of timedependent biologic processes responsible for disease activity and drug response we translate this understanding into medicines to provide demonstrable symptomatic relief from chronic neurologic disorders without additional tolerability issues with this platform we discover insights about temporal patterns of disease activity and drug response identify known drugs with potential activity in targeted disorders invent a synchronized drug profile to match underlying disease activity and drug response patterns develop new medicines that release the drug to match the desired drug profile first as single agents and then in fixeddose combinations commercialize new products alone and with partners our lead program ads  is a highdose amantadine taken oncedaily at bedtime in development for levodopainduced dyskinesia lid in people with parkinson’s diseased  a new drug application nda supporting ads for the treatment of levodopainduced dyskinesia in people with parkinson’s disease is currently under review by the us food and drug administration fda with a prescription drug user fee act pdufa action date of august    ads has additional opportunities to provide potentially symptomatic treatment of other chronic neurologic disorders such as multiple sclerosis walking impairment poststroke walking impairment and several other indications we are also investigating ads lacosamide for the treatment of partial onset seizures in patients with epilepsy additionally through our license to allergan our portfolio includes two medicines commercially available in the united states for indications relating to alzheimer’s disease namzaric® memantine hydrochloride extendedrelease and donepezil hydrochloride capsules and namenda xr® memantine hydrochloride extendedrelease capsules adamas is eligible to receive royalties on sales of namenda xr and namzaric beginning in june of  and may of  respectively our business strategy is to continue to discover develop and commercialize new treatment solutions for patients independently or in collaboration with partners namenda xr® and namzaric® are registered trademarks of merz pharma gmbh  co kgaa developing medicines to improve the daily lives of people affected by chronic neurologic disorders about adamas headquartersemeryville calif employees  initial public offering april  nasdaq adms adamas pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report adamas pharmaceuticals inc  product pipeline review   published by global markets direct product code  published august   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license adamas pharmaceuticals inc  product pipeline review   published august   content info  pages description summary global markets directs adamas pharmaceuticals inc  product pipeline review   provides an overview of the adamas pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of adamas pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of adamas pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of adamas pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the adamas pharmaceuticals incs pipeline products reasons to buy evaluate adamas pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of adamas pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the adamas pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of adamas pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of adamas pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of adamas pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures adamas pharmaceuticals inc snapshot adamas pharmaceuticals inc overview key information key facts adamas pharmaceuticals inc  research and development overview key therapeutic areas adamas pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities adamas pharmaceuticals inc  pipeline products glance adamas pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities adamas pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities adamas pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities adamas pharmaceuticals inc  unknown stage pipeline products unknown productscombination treatment modalities adamas pharmaceuticals inc  drug profiles amantadine hydrochloride er product description mechanism of action rd progress amantadine hydrochloride  oseltamivir phosphate  ribavirin product description mechanism of action rd progress ads product description mechanism of action rd progress ads product description mechanism of action rd progress ads product description mechanism of action rd progress ads product description mechanism of action rd progress memantine hydrochloride er  donepezil hydrochloride product description mechanism of action rd progress adamas pharmaceuticals inc  pipeline analysis adamas pharmaceuticals inc  pipeline products by target adamas pharmaceuticals inc  pipeline products by route of administration adamas pharmaceuticals inc  pipeline products by molecule type adamas pharmaceuticals inc  pipeline products by mechanism of action adamas pharmaceuticals inc  recent pipeline updates adamas pharmaceuticals inc  dormant projects adamas pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables adamas pharmaceuticals inc key information adamas pharmaceuticals inc key facts adamas pharmaceuticals inc  pipeline by indication  adamas pharmaceuticals inc  pipeline by stage of development  adamas pharmaceuticals inc  monotherapy products in pipeline  adamas pharmaceuticals inc  combination treatment modalities in pipeline  adamas pharmaceuticals inc  phase iii  adamas pharmaceuticals inc  phase ii  adamas pharmaceuticals inc  preclinical  adamas pharmaceuticals inc  discovery  adamas pharmaceuticals inc  unknown  adamas pharmaceuticals inc  pipeline by target  adamas pharmaceuticals inc  pipeline by route of administration  adamas pharmaceuticals inc  pipeline by molecule type  adamas pharmaceuticals inc  pipeline products by mechanism of action  adamas pharmaceuticals inc  recent pipeline updates  adamas pharmaceuticals inc  dormant developmental projects list of figures adamas pharmaceuticals inc  pipeline by top  indication  adamas pharmaceuticals inc  pipeline by stage of development  adamas pharmaceuticals inc  monotherapy products in pipeline  adamas pharmaceuticals inc  combination treatment modalities in pipeline  adamas pharmaceuticals inc  pipeline by top  target  adamas pharmaceuticals inc  pipeline by top  route of administration  adamas pharmaceuticals inc  pipeline by top  molecule type  adamas pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved adamas pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports adamas pharmaceuticals inc  product pipeline review   adamas pharmaceuticals inc  product pipeline review   wgr  august  global  pages global markets direct description table of content sample report enquiry before buy related reports adamas pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘adamas pharmaceuticals inc  product pipeline review  ’ provides an overview of the adamas pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of adamas pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of adamas pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of adamas pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the adamas pharmaceuticals inc’s pipeline productsreasons to buy evaluate adamas pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of adamas pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the adamas pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of adamas pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of adamas pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of adamas pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures adamas pharmaceuticals inc snapshot adamas pharmaceuticals inc overview key information key facts adamas pharmaceuticals inc  research and development overview key therapeutic areas adamas pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities adamas pharmaceuticals inc  pipeline products glance adamas pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities adamas pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities adamas pharmaceuticals inc  early stage pipeline products discovery productscombination treatment modalities adamas pharmaceuticals inc  unknown stage pipeline products unknown productscombination treatment modalities adamas pharmaceuticals inc  drug profiles memantine hydrochloride er  donepezil hydrochloride product description mechanism of action rd progress amantadine hydrochloride er product description mechanism of action rd progress amantadine  oseltamivir  ribavirin product description mechanism of action rd progress ads series product description mechanism of action rd progress ads series product description mechanism of action rd progress adamas pharmaceuticals inc  pipeline analysis adamas pharmaceuticals inc  pipeline products by target adamas pharmaceuticals inc  pipeline products by route of administration adamas pharmaceuticals inc  pipeline products by molecule type adamas pharmaceuticals inc  pipeline products by mechanism of action adamas pharmaceuticals inc  recent pipeline updates adamas pharmaceuticals inc  dormant projects adamas pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesadamas pharmaceuticals inc key information adamas pharmaceuticals inc key facts adamas pharmaceuticals inc  pipeline by indication  adamas pharmaceuticals inc  pipeline by stage of development  adamas pharmaceuticals inc  monotherapy products in pipeline  adamas pharmaceuticals inc  combination treatment modalities in pipeline  adamas pharmaceuticals inc  preregistration  adamas pharmaceuticals inc  phase iii  adamas pharmaceuticals inc  phase ii  adamas pharmaceuticals inc  discovery  adamas pharmaceuticals inc  unknown  adamas pharmaceuticals inc  pipeline by target  adamas pharmaceuticals inc  pipeline by route of administration  adamas pharmaceuticals inc  pipeline by molecule type  adamas pharmaceuticals inc  pipeline products by mechanism of action  adamas pharmaceuticals inc  recent pipeline updates  adamas pharmaceuticals inc  dormant developmental projects list of figuresadamas pharmaceuticals inc  pipeline by top  indication  adamas pharmaceuticals inc  pipeline by stage of development  adamas pharmaceuticals inc  monotherapy products in pipeline  adamas pharmaceuticals inc  combination treatment modalities in pipeline  adamas pharmaceuticals inc  pipeline by top  target  adamas pharmaceuticals inc  pipeline by top  route of administration  adamas pharmaceuticals inc  pipeline by top  molecule type  adamas pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send adamas pharmaceuticals inc private company information  bloomberg july    pm et biotechnology company overview of adamas pharmaceuticals inc snapshot people company overview adamas pharmaceuticals inc a pharmaceutical company discovers develops and sells chronosynchronous therapies for chronic neurologic disorders the company’s product portfolio comprises ads a chronosynchronous amantadine therapy for the treatment of levodopainduced dyskinesia in patients with parkinson’s disease its portfolio also comprises of namzaric memantine hydrochloride extendedrelease and donepezil hydrochloride capsules and namenda xr memantine hydrochloride extended release capsules for the treatment of moderate to severe alzheimer’s disease the company’s products under development include ads a chronosynchronous lacosamide therapy that has completed fir adamas pharmaceuticals inc a pharmaceutical company discovers develops and sells chronosynchronous therapies for chronic neurologic disorders the company’s product portfolio comprises ads a chronosynchronous amantadine therapy for the treatment of levodopainduced dyskinesia in patients with parkinson’s disease its portfolio also comprises of namzaric memantine hydrochloride extendedrelease and donepezil hydrochloride capsules and namenda xr memantine hydrochloride extended release capsules for the treatment of moderate to severe alzheimer’s disease the company’s products under development include ads a chronosynchronous lacosamide therapy that has completed first phase i clinical study for the treatment of partial onset seizures in patients with epilepsy the company was formerly known as neuromolecular pharmaceuticals inc and changed its name to adamas pharmaceuticals inc in july  adamas pharmaceuticals inc was founded in  and is headquartered in emeryville california detailed description  powell streetsuite emeryville ca united statesfounded in  employees phone  fax  wwwadamaspharmacom key executives for adamas pharmaceuticals inc dr gregory t went phd cofounder chairman  chief executive officer age  total annual compensation k dr rajiv patni md chief medical officer age  total annual compensation k ms jennifer j rhodes chief compliance officer chief business officer general counsel and corporate secretary age  total annual compensation k compensation as of fiscal year  adamas pharmaceuticals inc key developments adamas pharmaceuticals inc announces executive changes effective from june   jun   the board of directors of adamas pharmaceuticals inc appointed alfred g merriweather as the companys chief financial officer effective june   in such capacity mr merriweather will also serve as the companys principal financial officer and principal accounting officer before coming to the company he was chief financial officer at raindance technologies inc from november  to february  he was responsible for the finance information technology human resources and general legal functions in addition the company announced the retirement of william dawson the companys chief financial officer effective june   in connection with mr dawsons retirement on june   the company entered into a separation agreement with mr dawson pursuant to which a mr dawsons employment will terminate on september   b mr dawson ceased to be chief financial officer on june   adamas pharmaceuticals inc announces publication of results from phase iii parkinsons disease trial jun   adamas pharmaceuticals inc announced that results of its phase iii ease lid clinical trial of ads were published online in jama neurology a new drug application supporting ads amantadine extendedrelease capsules for the treatment of levodopainduced dyskinesia lid in people with parkinsons disease is under review by the fda with a prescription drug user fee act pdufa action date of august   adamas pharmaceuticals inc presents at jefferies  global healthcare conference jun  am jun   adamas pharmaceuticals inc presents at jefferies  global healthcare conference jun  am venue grand hyatt  e nd st new york new york united states speakers gregory t went cofounder chairman and chief executive officer similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states bertelsmann ag europe the advertising council inc united states rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact adamas pharmaceuticals inc please visit wwwadamaspharmacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close adamas pharmaceuticals inc  adms  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  generic drugs zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for adms all zacks’ analyst reports premium research for adms zacks rank hold  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores f value  f growth  f momentum  f vgm earnings esp  research report for adms snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank adamas pharmaceuticals inc adms aspen pharmacr apnhy acura pharmaceuticals inc acur akorn inc akrx allergan plc agn amphastar pharmaceuticals inc amph aquinox pharmaceuticals inc aqxp see all medical  generic drugs peers zacks news for adms adamas provides positive longterm data on parkinsons drug am est zacks adamas epilepsy drug shows positive result in phase ia study am est zacks adms what are zacks experts saying now zacks private portfolio services adamas pharmaceuticals adms in focus stock up  am est zacks mylan myl announces multiple generic launches in the us am est zacks mylanbiocons herceptin biosimilar phase iii data published am est zacks company summary adamas pharmaceuticals inc is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system the company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixeddose combination products adamas is currently developing ads its lead whollyowned product candidate for the treatment of levodopainduced dyskinesia lid associated with parkinsons disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment the companys portfolio also includes namzaric and namenda xr two approved products with forest laboratories holdings limited an indirect whollyowned subsidiary of allergan plc forest is responsible for marketing both products in the united states under an exclusive license from adamas financial information  adamas pharmaceuticals inc adamas contact home financial information first quarter  financial results adamas reports recent achievements and first quarter  financial results form q proxy statements date filed view apr   html pdf xls apr   html pdf xls form k date filed view feb   html pdf xls xbrl feb   html pdf xls xbrl form q date filed view may   html pdf xls xbrl nov   html pdf xls xbrl annual reports title view annual report  pdf  kb  annual report pdf  mb  annual report pdf  kb market report adamas pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing adamas pharmaceuticals inc  product pipeline review   aug    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs adamas pharmaceuticals inc  product pipeline review   provides an overview of the adamas pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of adamas pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasereport scopethe report provides brief overview of adamas pharmaceuticals inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of adamas pharmaceuticals incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the adamas pharmaceuticals incs pipeline productsreasons to get this reportevaluate adamas pharmaceuticals incs strategic position with total access to detailed information on its product pipelineassess the growth potential of adamas pharmaceuticals inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the adamas pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of adamas pharmaceuticals inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of adamas pharmaceuticals incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of adamas pharmaceuticals inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contents list of tables list of figures adamas pharmaceuticals inc snapshot adamas pharmaceuticals inc overview key information key facts adamas pharmaceuticals inc  research and development overview key therapeutic areas adamas pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities adamas pharmaceuticals inc  pipeline products glance adamas pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities adamas pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities adamas pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities adamas pharmaceuticals inc  unknown stage pipeline products unknown productscombination treatment modalities adamas pharmaceuticals inc  drug profiles amantadine hydrochloride er product description mechanism of action rd progress amantadine hydrochloride  oseltamivir phosphate  ribavirin product description mechanism of action rd progress ads product description mechanism of action rd progress ads product description mechanism of action rd progress ads product description mechanism of action rd progress ads product description mechanism of action rd progress memantine hydrochloride er  donepezil hydrochloride product description mechanism of action rd progress adamas pharmaceuticals inc  pipeline analysis adamas pharmaceuticals inc  pipeline products by target adamas pharmaceuticals inc  pipeline products by route of administration adamas pharmaceuticals inc  pipeline products by molecule type adamas pharmaceuticals inc  pipeline products by mechanism of action adamas pharmaceuticals inc  recent pipeline updates adamas pharmaceuticals inc  dormant projects adamas pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesadamas pharmaceuticals inc key information adamas pharmaceuticals inc key facts adamas pharmaceuticals inc  pipeline by indication  adamas pharmaceuticals inc  pipeline by stage of development  adamas pharmaceuticals inc  monotherapy products in pipeline  adamas pharmaceuticals inc  combination treatment modalities in pipeline  adamas pharmaceuticals inc  phase iii  adamas pharmaceuticals inc  phase ii  adamas pharmaceuticals inc  preclinical  adamas pharmaceuticals inc  discovery  adamas pharmaceuticals inc  unknown  adamas pharmaceuticals inc  pipeline by target  adamas pharmaceuticals inc  pipeline by route of administration  adamas pharmaceuticals inc  pipeline by molecule type  adamas pharmaceuticals inc  pipeline products by mechanism of action  adamas pharmaceuticals inc  recent pipeline updates  adamas pharmaceuticals inc  dormant developmental projects list of figuresadamas pharmaceuticals inc  pipeline by top  indication  adamas pharmaceuticals inc  pipeline by stage of development  adamas pharmaceuticals inc  monotherapy products in pipeline  adamas pharmaceuticals inc  combination treatment modalities in pipeline  adamas pharmaceuticals inc  pipeline by top  target  adamas pharmaceuticals inc  pipeline by top  route of administration  adamas pharmaceuticals inc  pipeline by top  molecule type  adamas pharmaceuticals inc  pipeline products by top  mechanism of action   companies mentioned in this reportadamas pharmaceuticals inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc adamas pharmaceuticals inc  ipo candy skip to primary navigation skip to content becomeamember ipo candyeveryones favorite site for ipo insights and analysismain navigationhome » adamas pharmaceuticals incadamas pharmaceuticals inc  by adamas pharmaceuticals inc a specialty pharmaceutical company focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems the company’s lead product candidate ads is in phase  clinical development for the treatment of a movement disorder known as levodopainduced dyskinesia associated with parkinson’s disease ads is also in a phase  clinical study for the treatment of symptoms associated with various sclerosis including walking impairment the company’s portfolio also includes namzaric memantine hcl extended release and donepezil hcl capsules and namenda xr memantine hci extended release capsules it has a licensing agreement with forest laboratories holdings limited for marketing namzaric and namenda xr the company was formerly known as neuromolecular pharmaceuticals inc and changed its name to adamas pharmaceuticals inc in july  adamas pharmaceuticals inc was founded in  and is headquartered in emeryville california adamas pharmaceuticals inc adamas pharmaceuticals inc a specialty pharmaceutical company focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems the company’s lead product candidate ads is in phase  clinical development for the treatment of a movement disorder known as levodopainduced dyskinesia associated with parkinson’s disease ads is also in a phase  clinical study for the treatment of symptoms associated with various sclerosis including walking impairment the company’s portfolio also includes namzaric memantine hcl extended release and donepezil hcl capsules and namenda xr memantine hci extended release capsules it has a licensing agreement with forest laboratories holdings limited for marketing namzaric and namenda xr the company was formerly known as neuromolecular pharmaceuticals inc and changed its name to adamas pharmaceuticals inc in july  adamas pharmaceuticals inc was founded in  and is headquartered in emeryville california twitter facebook google linkedin adamas pharmaceuticals incpadamas pharmaceuticals inc a specialty pharmaceutical company focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems the company’s lead product candidate ads is in phase  clinical development for the treatment of a movement disorder known as levodopainduced dyskinesia associated with parkinson’s disease ads is also in a phase  clinical study for the treatment of symptoms associated with various sclerosis including walking impairment the company’s portfolio also includes namzaric memantine hcl extended release and donepezil hcl capsules and namenda xr memantine hci extended release capsules it has a licensing agreement with forest laboratories holdings limited for marketing namzaric and namenda xr the company was formerly known as neuromolecular pharmaceuticals inc and changed its name to adamas pharmaceuticals inc in july  adamas pharmaceuticals inc was founded in  and is headquartered in emeryville californiap caunited statesphone  adms drugs for chronic cns disorders documents roadshow main categoryhealthcare categoriesdrugs contact httpwwwadamaspharmacom  address powell street suite  emeryville california  united states we love ipos the ipo market provides a magical window into the most exciting technologies emerging consumer trends and important business developments  all testing their mettle in the crucible of the public markets we are constantly learning and researching to deliver the best insights available we are independent we have no vested interests driving our work all the investment banks and brokers on a deal are paid to do a sales and marketing job our job is to remain objective and use a factbased approach to evaluate the potential for an ipo we get the best ratings ipo candy has been recognized since  as the single best place to get commentary analysis and assets in the ipo market the most common writein comment we get from users is that they love what we do we share everything we know with three decades of research under our belt we want to share what we have learned and the best practices we have discovered our ipo university contains texts videos and resources to share our process and help everyone develop their skills become an ipocandy member enjoy the benefits of full access to our content including access to ipo roadshow slideshows and transcripts included in our posts members also get additional insights via email receive our monthly candygram and have access to our ipo calendar become a member admsnasdaq gm stock quote  adamas pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist adamas pharmaceuticals inc admsus nasdaq gm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  adamas reports inducement grant to new chief financial officer  multiple sclerosis drugs and therapeutic pipeline review h  research available at rnr market research  adamas appoints new chief financial officer  adamas announces publication of ads phase  ease lid clinical trial in jama neurology  adamas presents expanded analysis from the ads openlabel study showing tolerability and durability out to  weeks  adamas to present at two upcoming investor conferences  adamas presents positive phase a data of ads lacosamide for the treatment of partial onset seizures in epilepsy  adamas signs  million royaltybacked note agreement with healthcare royalty partners  adamas reports recent achievements and first quarter  financial results  adamas reports inducement grant to new chief operating officer there are currently no press releases for this ticker please check back later profile adamas pharmaceuticals inc is a specialty pharmaceutical company the company develops drugs to improve the lives of those affected by chronic disorders of the central nervous system adamas pharmaceuticals seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixeddose combination products address  powell streetsuite emeryville ca united states phone  website wwwadamaspharmacom executives board members gregory t went chairmanceocofounder alfred g merriweather chief financial officer rajiv patni chief medical officer richard a king chief operating officer jennifer j rhodes coochief bus ofcrsecretarygen cnsl show more adamas pharmaceuticals  homepage adamas contact home the time is rightdeveloping therapies for people with chronic neurologic disorders overviewadamas develops new medicines to improve the lives of people affected by chronic neurologic disorders about adamas ads in levodopainduced dyskinesiawe are developing an amantadine therapy for the treatment of levodopainduced dyskinesia in people with parkinsons disease learn more product pipeline overview adamas develops new medicines to improve the lives of people affected by chronic neurologic disorders about adamas recent news adamas reports inducement grant to new chief financial officer jul   adamas appoints new chief financial officer jun   adamas announces publication of ads phase  ease lid clinical trial in jama neurology jun   adamas presents expanded analysis from the ads openlabel study showing tolerability and durability out to  weeks jun   adamas to present at two upcoming investor conferences jun   bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one